MA44378A - Protéines de fusion immunogènes pour le traitement du cancer - Google Patents
Protéines de fusion immunogènes pour le traitement du cancerInfo
- Publication number
- MA44378A MA44378A MA044378A MA44378A MA44378A MA 44378 A MA44378 A MA 44378A MA 044378 A MA044378 A MA 044378A MA 44378 A MA44378 A MA 44378A MA 44378 A MA44378 A MA 44378A
- Authority
- MA
- Morocco
- Prior art keywords
- fusion proteins
- cancer treatment
- immunogen fusion
- immunogen
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03005—5'-Nucleotidase (3.1.3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562146654P | 2015-04-13 | 2015-04-13 | |
US201562146626P | 2015-04-13 | 2015-04-13 | |
US201562263174P | 2015-12-04 | 2015-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA44378A true MA44378A (fr) | 2019-01-23 |
Family
ID=55808893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA044378A MA44378A (fr) | 2015-04-13 | 2016-04-12 | Protéines de fusion immunogènes pour le traitement du cancer |
Country Status (11)
Country | Link |
---|---|
US (2) | US9808516B2 (fr) |
EP (1) | EP3283100A2 (fr) |
JP (1) | JP2018512165A (fr) |
CN (1) | CN107980044A (fr) |
AU (1) | AU2016247894A1 (fr) |
CA (1) | CA2982543A1 (fr) |
HK (2) | HK1250731A1 (fr) |
MA (1) | MA44378A (fr) |
TW (1) | TW201704267A (fr) |
UY (1) | UY36617A (fr) |
WO (1) | WO2016168214A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA037778B1 (ru) | 2013-10-18 | 2021-05-20 | Дойчес Кребсфоршунгсцентрум | Меченые ингибиторы простатического специфического мембранного антигена (псма), их применение в качестве агентов для визуализации и фармацевтических агентов для лечения рака предстательной железы |
JP2018512165A (ja) | 2015-04-13 | 2018-05-17 | アデュロ バイオテック,インコーポレイテッド | 癌の治療のための免疫原性融合タンパク質 |
MX2017013174A (es) | 2015-04-13 | 2018-04-11 | Aduro Biotech Inc | Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos. |
WO2017106638A1 (fr) | 2015-12-16 | 2017-06-22 | Gritstone Oncology, Inc. | Identification de néogènes, fabrication et utilisation |
EP3694532A4 (fr) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | Identification de néo-antigènes au moyen de points chauds |
AU2018373154A1 (en) | 2017-11-22 | 2020-07-02 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
CN118290563B (zh) * | 2024-06-03 | 2024-08-02 | 磐如生物科技(天津)有限公司 | 一种前列腺癌抗原肽和免疫佐剂组合物及其在抗肿瘤中的应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
JP4620808B2 (ja) | 1994-11-28 | 2011-01-26 | トーマス・ジェファーソン・ユニバーシティ | 突然変異上皮成長因子受容体を標的とする試薬および方法 |
JP2004500405A (ja) | 2000-03-29 | 2004-01-08 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア | 抗原の免疫原性を増強するための組成物および方法 |
WO2004006837A2 (fr) | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Vaccins a la mesotheline et systemes de modele |
EP2311978A1 (fr) | 2002-08-20 | 2011-04-20 | Millennium Pharmaceuticals, Inc. | Compositions, kits et procédés d'identification, évaluation, prévention et thérapie du cancer du col de lutérus |
JP4545151B2 (ja) | 2003-02-06 | 2010-09-15 | シーラス コーポレイション | 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法 |
EP1592442A2 (fr) | 2003-02-06 | 2005-11-09 | Cerus Corporation | Microbes modifies vivant en milieu naturel, compositions de vaccins, et procedes d'utilisation correspondants |
JP5283335B2 (ja) | 2003-06-17 | 2013-09-04 | マンカインド コーポレイション | 各種癌の治療を目的とした腫瘍関連抗原の組合せ |
US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
WO2007117371A2 (fr) | 2006-03-01 | 2007-10-18 | Anza Therapeutics, Inc. | Listeria de fabrication humaine et ses procédés d'utilisation |
EP2860253B1 (fr) | 2006-03-01 | 2018-08-01 | Aduro Biotech, Inc. | Listéria génétiquement modifiée et procédés pour son utilisation |
WO2012068360A1 (fr) * | 2010-11-17 | 2012-05-24 | Aduro Biotech | Procédés et compositions pour l'induction d'une réponse immunitaire vis-à-vis d'egfrviii |
JP6054942B2 (ja) * | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法 |
WO2014106123A1 (fr) * | 2012-12-27 | 2014-07-03 | Aduro Biotech, Inc. | Partenaires de fusion de type peptides signal favorisant l'expression de séquences antigéniques dans les bactéries du genre listeria et leurs procédés de préparation et d'utilisation |
US9388243B2 (en) | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
MX2017013174A (es) | 2015-04-13 | 2018-04-11 | Aduro Biotech Inc | Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos. |
JP2018512165A (ja) | 2015-04-13 | 2018-05-17 | アデュロ バイオテック,インコーポレイテッド | 癌の治療のための免疫原性融合タンパク質 |
-
2016
- 2016-04-12 JP JP2017554394A patent/JP2018512165A/ja active Pending
- 2016-04-12 AU AU2016247894A patent/AU2016247894A1/en not_active Abandoned
- 2016-04-12 TW TW105111338A patent/TW201704267A/zh unknown
- 2016-04-12 US US15/097,271 patent/US9808516B2/en not_active Expired - Fee Related
- 2016-04-12 WO PCT/US2016/027167 patent/WO2016168214A2/fr unknown
- 2016-04-12 EP EP16718591.7A patent/EP3283100A2/fr not_active Withdrawn
- 2016-04-12 UY UY0001036617A patent/UY36617A/es not_active Application Discontinuation
- 2016-04-12 CA CA2982543A patent/CA2982543A1/fr not_active Abandoned
- 2016-04-12 CN CN201680033909.4A patent/CN107980044A/zh active Pending
- 2016-04-12 MA MA044378A patent/MA44378A/fr unknown
-
2017
- 2017-09-29 US US15/721,641 patent/US20180085446A1/en not_active Abandoned
-
2018
- 2018-08-06 HK HK18110072.0A patent/HK1250731A1/zh unknown
- 2018-08-09 HK HK18110240.7A patent/HK1250662A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW201704267A (zh) | 2017-02-01 |
CA2982543A1 (fr) | 2016-10-20 |
AU2016247894A1 (en) | 2017-10-26 |
UY36617A (es) | 2016-10-31 |
US20160324945A1 (en) | 2016-11-10 |
HK1250662A1 (zh) | 2019-01-11 |
WO2016168214A2 (fr) | 2016-10-20 |
US20180085446A1 (en) | 2018-03-29 |
EP3283100A2 (fr) | 2018-02-21 |
CN107980044A (zh) | 2018-05-01 |
WO2016168214A3 (fr) | 2016-12-22 |
US9808516B2 (en) | 2017-11-07 |
JP2018512165A (ja) | 2018-05-17 |
HK1250731A1 (zh) | 2019-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
HK1245134A1 (zh) | 用抗lap單克隆抗體治療癌症 | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
MA45429A (fr) | Polythérapie pour le traitement du cancer | |
MA41555A (fr) | Polythérapie pour le traitement du cancer | |
DK3474841T3 (da) | Fremgangsmåder til behandling af ar+-brystkræft | |
MA47121A (fr) | Molécules de liaison pour le traitement du cancer | |
MA44378A (fr) | Protéines de fusion immunogènes pour le traitement du cancer | |
MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA41123A (fr) | Polythérapie pour le traitement du cancer | |
MA43587A (fr) | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
FR3036518B1 (fr) | Inversion pour contrainte tectonique | |
DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
FR3042807B1 (fr) | Autolestage pour banche de coffrage | |
GB201618424D0 (en) | Treatment of antibody mediated disease | |
IL265178A (en) | Antibody for the treatment of autoimmune diseases | |
FR3026299B1 (fr) | Procede cosmetique pour attenuer les rides | |
FR3021541B1 (fr) | Procede cosmetique pour attenuer les rides | |
MA47474A (fr) | Polythérapie rationelle pour le traitement du cancer | |
KR20180084983A (ko) | 암의 치료를 위한 피리미도-피리미다지논의 용도 |